Search form



CL Mobile Menu

Drug Benefit Trends

Drug Benefit Trends

Owing to the recent senatorial election results in Massachusetts, anticipated health care reform agendas for the United States are undergoing change again as the electorate and Congress struggle with a burgeoning health care system.

In the metastatic setting, given the limited potential for a cure, treatment is focused on extending patient life, providing symptom relief, and improving quality of life.

Adults aged 18 to 64 years enrolled in high-deductible health plans (HDHPs) with or without a flexible spending account (FSA) may be less likely to have their medical and prescription drug needs met because of cost than those adults with traditional health plans and consumer-directed health plans (CDHPs)

In the days before a vote is expected, the near-final version of the health care reform bill seems to have taken shape. Before they fine-tune the bill, however, Democrats must wait for the cost assessment from the Congressional Budget Office.

The editors of Drug Benefit Trends interviewed Peter Juhn, MD, MPH, president of the Therapeutic Resource Centers division at Medco Health Solutions, Inc. Click below to hear him discuss the TRC program, launched in 2007, which monitors prescription drug use in patients with specific chronic conditions and is designed to close gaps in care.

Sporotrichosis is a fungal infection that typically results in cutaneous or lymphocutaneous disease, although other, more severe, life-threatening manifestations do occur. This article reviews updated treatment guidelines, which state that itraconazole has become the preferred therapy for most forms of infection. Amphotericin B remains the mainstay of treatment for severe cases, but lipid formulations are now preferred because of their more favorable toxicity profile. Also, fluconazole has been shown to be less effective than itraconazole and is no longer recommended except as an alternative for cutaneous and lymphocutaneous disease. [Drug Benefit Trends. 2010;22:49-52]

The US decision to freeze spending on HIV programs in several African countries has caused concern that some of the progress made in the global AIDS epidemic will be reversed.


Subscribe to Drug Benefit Trends on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.